Paysign (PAYS) CEO Mark Newcomer receives performance share award, withholds shares for taxes
Paysign Inc. CEO Mark Newcomer received an equity compensation award of 133,334 performance-based restricted shares, which vested on May 20, 2026, due to the achievement of specific earnings targets. To cover tax withholding obligations, 78,701 of these shares were disposed of back to the issuer at $6.15 per share. After these transactions, Newcomer's direct holdings increased to 9,084,062 shares of Paysign common stock.
Paysign (PAYS) CPO receives 22,222 share grant as restricted stock vests
Paysign, Inc.'s Chief Payments Officer, Matthew Louis Lanford, reported equity compensation activity where 22,222 performance-based restricted shares vested on May 18, 2026. To cover tax obligations, 12,755 shares were withheld by the company at $5.865 per share. After these transactions, Lanford directly holds 202,920 shares of Paysign common stock, reflecting compensation vesting and tax withholding rather than open-market trading.
PAYS
Paysign, Inc. (PAYS) reported strong financial performance in Q1 2026, with revenue growing 50.8% to $28 million, exceeding guidance, and net income increasing 110% to $5.4 million. This growth was primarily driven by its patient affordability and plasma segments, with improved gross profit margins and increased income before taxes. The company provided optimistic full-year 2026 revenue guidance of $106.5 million to $110.5 million, highlighting confidence in continued growth despite some operational challenges and the absence of share repurchases.
Assessing Paysign (PAYS) Valuation After Record Q1 Results And Patient Affordability Shift
Paysign (PAYS) recently reported record Q1 2026 results, driven significantly by its patient affordability business. Despite recent share price volatility, the stock has shown strong momentum historically. The article discusses Paysign's valuation, highlighting a "most popular narrative" that suggests the stock is undervalued with a fair value of $12.00, while also noting a higher P/E ratio compared to peers.
Is Paysign’s (PAYS) Affordability Shift Redefining Its Core Profit Engine?
Paysign, Inc. (PAYS) recently reported strong Q1 2026 results, with patient affordability programs becoming its largest revenue contributor, indicating a strategic shift towards higher-margin pharmaceutical offerings. This change in revenue mix is critical for its profitability and growth, reinforced by the company's 2026 guidance. While this shift diversifies Paysign away from plasma cards, investors should consider the associated execution risks and the concentration in a few healthcare segments.
Paysign (PAYS) EVP stock vests; shares withheld for taxes
Paysign, Inc. EVP of Operations, Joan M. Herman, had 11,111 shares of performance-based restricted stock vest on May 13, 2026. To cover tax obligations from this vesting, 6,171 shares were withheld by the issuer at $5.83 per share. These are routine compensation-related transactions, and after them, Herman directly holds 842,694 shares of Paysign common stock.
Is Paysign’s (PAYS) Affordability Shift Redefining Its Core Profit Engine?
Paysign's first-quarter 2026 results show a significant shift, with patient affordability programs becoming the largest revenue contributor, indicating a move towards higher-margin pharmaceutical offerings. This change supports the company's investment narrative of profitable growth through high-margin programs, despite potential risks from concentration in a few healthcare niches and rising costs. While the Q1 performance is strong and aligns with full-year guidance, investors should consider the execution risk associated with sustaining margins amid new investments.
PaySign, Inc. (NASDAQ:PAYS) Q1 2026 Earnings Call Transcript
PaySign, Inc. reported its strongest first quarter in company history for Q1 2026, with revenue growing 50.8% to $28 million and net income increasing 110% to $5.4 million. The patient affordability business saw significant growth, becoming the largest revenue contributor, while the plasma donor compensation business also showed a 25% increase in revenue. The company is confident in achieving the upper end of its 2026 guidance, driven by a robust pipeline in patient affordability and ongoing efficiencies in plasma operations.
Paysign projects 2026 revenue of $106.5M-$110.5M while targeting 147-150 active patient affordability programs by Q2
Paysign (NASDAQ: PAYS) announced its 2026 financial projections, targeting revenues between $106.5 million and $110.5 million. The company also aims to have 147 to 150 active patient affordability programs by the second quarter of 2026, signaling strong growth in its specialized segment. These projections highlight Paysign's strategic focus on expanding its presence in patient affordability solutions.
Paysign’s Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026
Paysign, Inc. (NASDAQ: PAYS) announced exceptional financial results for the first quarter of 2026, driven by a 50.8% increase in total revenues to $28.04 million. This strong performance was primarily fueled by its patient affordability offerings in the pharma industry, which saw an 81.9% revenue increase, and robust growth in its plasma donor compensation business. The company also reported significant margin expansion, with operating margin rising to 23.8% and adjusted EBITDA increasing by 113.4%, alongside a positive outlook for the remainder of 2026.
Paysign stock maintains Buy rating at DA Davidson on strong Q1 beat
DA Davidson reiterated a Buy rating and a $9.00 price target on Paysign Inc. (NASDAQ:PAYS) following its robust first-quarter earnings report, which saw significant revenue and adjusted EBITDA growth. The company's Q1 results surpassed forecasts, with management also affirming its positive 2026 guidance for revenue and adjusted EBITDA. Despite a slight aftermarket stock decline, the strong performance highlights Paysign's current financial trajectory and ability to exceed market expectations.
Paysign, Inc. 1Q 2026: Revenue $28.04M, EPS $0.09— 10-Q Summary
Paysign, Inc. reported strong first-quarter 2026 results, with revenue increasing to $28.04 million and diluted EPS reaching $0.09. This growth was primarily fueled by significant expansion in the company's pharma and plasma verticals, alongside increased load volumes compared to the previous year. The company also improved its gross margin to 65% through strategic investments in technology, cybersecurity, customer service, and platform integrations.
Net income at Paysign (NASDAQ: PAYS) rises 110.3% in Q1 2026
Paysign (NASDAQ: PAYS) reported a strong Q1 2026 with net income increasing by 110.3% to $5,438,918 and revenue rising 50.8% to $28,038,424. This growth was primarily driven by significant increases in revenue from both the plasma and pharma industries, boosted by the addition of new centers and programs. The company
Paysign (NASDAQ: PAYS) investors reelect full board and back Baker Tilly
Paysign, Inc. (NASDAQ: PAYS) stockholders reelected the full board of seven directors, including Mark R. Newcomer and Dennis L. Triplett, at their Annual Meeting on May 8, 2026. Shareholders also overwhelmingly ratified Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The election results demonstrate strong shareholder support for the current leadership and auditor.
Earnings call transcript: Paysign Inc. Q1 2026 beats EPS expectations
Paysign Inc. reported strong first-quarter 2026 results, surpassing EPS and revenue expectations with an actual EPS of $0.09 and revenue of $28.04 million. The company saw a 50.8% year-over-year revenue increase, driven significantly by an 81.9% surge in pharma industry revenue, which for the first time exceeded plasma revenue. Despite these positive financial outcomes, Paysign's stock experienced a slight aftermarket decline of 0.75%.
Paysign falls over 6% despite beating Q1 estimates
Paysign, Inc. reported strong first-quarter results, exceeding analyst expectations for both adjusted earnings per share and revenue. Despite this positive performance, the company's shares fell by 6.7% due to Q2 and full-year guidance that came in below Wall Street estimates. Both pharma and plasma revenue saw significant increases, and the company expanded its operating margin and adjusted EBITDA.
Paysign’s Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026
Paysign, Inc. announced strong financial results for the first quarter of 2026, driven by a 50.8% increase in total revenue to $28.04 million. This growth was significantly boosted by its patient affordability offerings, with pharma revenue up 81.9%, and solid performance from its plasma donor compensation business. The company also achieved substantial margin expansion and reported a net income of $5.44 million, reflecting the scalability of its platform and strategic investments.
Paysign (NASDAQ: PAYS) posts 51% Q1 growth and reaffirms strong 2026 outlook
Paysign (NASDAQ: PAYS) reported significant growth in Q1 2026, with revenue increasing by 50.8% to $28.04 million, driven by strong performance in its patient affordability and plasma programs. Net income more than doubled to $5.44 million, and the company reaffirmed its robust 2026 guidance, expecting continued revenue growth and margin expansion. Paysign exited the quarter with a strong cash position and no bank debt, positioning it well for future investments.
Thanks to the strong performance of its patient payment affordability solutions, Paysign Inc achieved a 51% revenue growth in the first quarter of 2026, while profit margins also saw significant improvement.
Paysign Inc. reported a significant 51% revenue growth in the first quarter of 2026, driven by the strong performance of its patient payment affordability solutions. The company also saw substantial improvement in profit margins, indicating successful market penetration and operational efficiency within the medical payment sector.
Paysign posts Q1 2026 revenue $28.04M, net income $5.44M and adjusted diluted EPS $0.17
Paysign reported strong first-quarter 2026 results, with revenue increasing by 50.8% to $28.04 million and net income rising to $5.44 million. Adjusted diluted EPS reached $0.17, driven by significant growth in both its pharma and plasma businesses. The company also exited the quarter with a healthy cash balance and no bank debt, alongside improved margins.
TradingKey
This page on TradingKey provides an overview of Paysign Inc. (PAYS), including its current stock price, market cap, and P/E TTM. It shows the stock trading at $6.440, down 3.88%, with a market cap of $354.76M. The page also offers sections for financials, discussions, and analysis, and includes disclaimers about delayed quotes and investment risks.
Paysign Q1 2026 earnings preview
This article provides a Q1 2026 earnings preview for Paysign, a company whose stock has seen significant short interest. It highlights the expected earnings per share (EPS) of $0.05 and revenue of $12.35 million, alongside recent analyst revisions and the company's past performance.
Paysign (Nasdaq:PAYS) - Stock Analysis
This article provides a detailed stock analysis of Paysign (Nasdaq:PAYS), highlighting its financial performance, future growth prospects, and analyst sentiments. Paysign, a provider of prepaid card programs and payment solutions, is reported to be 48.2% undervalued with a fair value of US$12.00, despite significant share price volatility. The company forecasts strong revenue and earnings growth, particularly driven by its patient affordability and digital payments segments.
Paysign EVP Joan Herman sells $46,737 in company stock By Investing.com
Joan M. Herman, Executive Vice President of Operations and a Director at Paysign, Inc. (NASDAQ:PAYS), sold 6,667 shares of company stock for approximately $46,737 on May 4, 2026, executing a Rule 10b5-1 trading plan. Following the transaction, she directly holds 831,583 shares. This sale comes as the stock currently trades below the sale price but has shown a remarkable 172% return over the past year, with InvestingPro analysis suggesting it is undervalued.
Paysign EVP Joan Herman sells $46,737 in company stock By Investing.com
Joan M. Herman, EVP of Operations and Director at Paysign, Inc. (NASDAQ:PAYS), sold 6,667 shares totaling approximately $46,737 on May 4, 2026. This sale was conducted via a Rule 10b5-1 trading plan adopted in September 2025. Despite the sale occurring at $7.0102 per share, the stock currently trades lower at $6.53, though it has seen a significant 172% return over the past year.
Paysign (NASDAQ:PAYS) EVP Joan Herman Sells 6,667 Shares
Paysign (NASDAQ:PAYS) EVP Joan Herman sold 6,667 shares of the company's stock on May 4th at an average price of $7.01, totaling $46,735.67. This transaction, executed under a Rule 10b5-1 trading plan, reduced her direct ownership by 0.80% to 831,583 shares. The company's stock is currently trading at $6.53 with a market cap of $360.39 million, and analysts have a "Moderate Buy" consensus rating with a target price of $9.42.
Insider Sell: Joan Herman Sells 6,667 Shares of PaySign Inc (PAYS)
Joan Herman, Executive Vice President of Operations at PaySign Inc, sold 6,667 shares of the company on May 4, 2026, reducing her holdings to 831,583 shares. This transaction is part of a trend showing more insider selling than buying at PaySign Inc over the past year. The stock was trading at $7.01, and GuruFocus deemed it "modestly overvalued" with a price-to-GF-Value ratio of 1.24.
Paysign EVP Joan Herman sells $46,737 in company stock
Paysign's EVP of Operations, Joan Herman, sold 6,667 shares of company stock for approximately $46,737 at an average price of $7.0102 per share. This sale was part of a pre-arranged trading plan, and she still directly holds over 831,000 shares. The company recently reported strong Q4 2025 earnings with significant revenue and adjusted EBITDA growth, leading DA Davidson to reiterate a Buy rating.
Executive at Paysign (NASDAQ: PAYS) sells 6,667 shares
Joan M. Herman, EVP of Operations and a director at Paysign, Inc. (NASDAQ: PAYS), sold 6,667 shares of common stock at a weighted average price of $7.0102 per share. This transaction, executed on May 4, 2026, was part of a pre-arranged Rule 10b5-1 trading plan adopted in September 2025. Following the sale, Herman retains 831,583 shares of Paysign common stock.
Paysign (PAYS) to Release Earnings on Tuesday
Paysign (PAYS) is scheduled to release its Q1 2026 earnings after market close on Tuesday, May 12th, with analysts expecting $0.07 EPS and $27.01 million in revenue. The company previously missed EPS estimates in Q4 but beat revenue, and analysts project $1.00 EPS for both the current and next fiscal year. Shares are trading around $6.74, with institutional ownership at approximately 25.9% and a consensus "Moderate Buy" rating with an average target price of $9.42.
Short Interest in Paysign, Inc. (NASDAQ:PAYS) Decreases By 26.4%
Paysign, Inc. (NASDAQ:PAYS) experienced a 26.4% decrease in short interest during April, reducing the total to 1,685,717 shares. This represents approximately 4.0% of the company's shares sold short, resulting in a short-interest ratio of 1.7 days. Institutional investors hold 25.89% of the stock, with several firms increasing their stakes, and analysts maintain a "Moderate Buy" rating with a consensus target price of $9.42 amidst recent mixed earnings results.
Paysign, Inc. (NASDAQ:PAYS) Short Interest Up 36.7% in March
Paysign, Inc. (NASDAQ:PAYS) experienced a significant 36.7% increase in short interest in March, reaching 2,289,773 shares. Despite missing EPS estimates, the company's revenue topped expectations, and its stock traded up by 1.4% recently. Analysts maintain a "Moderate Buy" consensus rating with a target price of $9.42, and institutional investors have been actively adjusting their positions.
Paysign to Host First Quarter 2026 Earnings Call
Paysign, Inc. (NASDAQ: PAYS) announced it will host its first quarter 2026 earnings call on Tuesday, May 12, 2026, at 5:00 p.m. Eastern time. The company, a provider of patient affordability and donor compensation solutions, provided dial-in and webcast details for participants, with a replay available until August 12, 2026. Financial professionals wishing to ask questions must register by emailing [email protected] by May 8, 2026.
PaySign Adjusts Valuation Grade Amid Strong Market Performance and Institutional Confidence
PaySign, Inc. has recently had its valuation grade adjusted to "fair," reflecting a balanced view of its financial metrics, including a P/E ratio of 26 and a Return on Equity of 16.53%. The microcap company has significantly outperformed the S&P 500 over the past year with a 161.40% return, and robust institutional confidence is indicated by 50.32% holdings and a recent 4.72% increase in their stake. This adjustment highlights PaySign's evolving market position and strong performance.
Analysts Offer Insights on Technology Companies: PaySign (PAYS), BlackBerry (BB) and Microsoft (MSFT)
The article highlights recent analyst ratings for three technology companies: PaySign (PAYS), BlackBerry (BB), and Microsoft (MSFT). Analysts from Barrington, CIBC, and Bank of America Securities maintained Buy ratings for these respective companies, with specific price targets and reported upsides. The sentiment across the board for these companies in the technology sector is largely bullish.
Analysts Offer Insights on Technology Companies: PaySign (PAYS), BlackBerry (BB) and Microsoft (MSFT)
Three analysts recently provided bullish sentiments on technology companies PaySign (PAYS), BlackBerry (BB), and Microsoft (MSFT). Gary Prestopino of Barrington maintained a Buy rating on PaySign with an $8.50 price target, while Todd Coupland from CIBC maintained a Buy rating on BlackBerry with a $6.00 price target. Bank of America Securities analyst Tal Liani also maintained a Buy rating on Microsoft, highlighting a consensus Strong Buy rating with an average target of $586.30.
Paysign (NASDAQ:PAYS) Rating Increased to Buy at Wall Street Zen
Wall Street Zen has upgraded Paysign (NASDAQ:PAYS) from a "hold" to a "buy" rating, contributing to an overall "Moderate Buy" consensus among analysts with a price target of $9.42. This upgrade follows Paysign reporting Q4 earnings of $0.02 EPS, slightly missing estimates, but exceeding revenue expectations with $22.76 million. Institutional investors, including Punch & Associates, have significantly increased their stakes in the company, which specializes in prepaid payment solutions.
Paysign (PAYS) Is Up 67.6% After Strong 2026 Margin Guidance And Revenue Outlook - Has The Bull Case Changed?
Paysign (PAYS) recently announced strong 2026 guidance, including projected revenue of US$106.5–110.5 million and operating margins of 20–22%, which has positively impacted its stock price. The new outlook, especially the expected margin expansion from patient affordability programs, is reshaping the investment narrative. However, the company still faces concentration risk in plasma and pharma reimbursement sectors.
Paysign (PAYS) Is Up 67.6% After Strong 2026 Margin Guidance And Revenue Outlook - Has The Bull Case Changed?
Paysign (PAYS) has seen a significant stock increase following robust 2026 revenue and margin guidance, including projected Q1 revenue of US$27.0–27.5 million and full-year revenue of US$106.5–110.5 million, with improved operating and net margins. This guidance is driven by higher-margin patient affordability programs and a balanced plasma/pharma mix. Despite the positive outlook, the article notes the remaining concentration risk in its core markets as a key vulnerability.
Paysign (PAYS) Is Up 67.6% After Strong 2026 Margin Guidance And Revenue Outlook - Has The Bull Case Changed?
Paysign Inc. (PAYS) reported strong fourth-quarter 2025 revenue and provided optimistic 2026 guidance, including increased revenue projections and expanded operating and net margins, largely driven by higher-margin patient affordability programs. This positive outlook has led to a significant 67.6% stock increase. However, the company still faces concentration risks due to its heavy reliance on plasma and pharma payment solutions, which some analysts view with caution.
Paysign Inc. Earnings Call Highlights Rapid Profit Surge
Paysign Inc.'s Q4 earnings call revealed significant growth, with total revenue for fiscal 2025 reaching $82.0 million, a 40.5% increase year-over-year. Net income nearly doubled to $7.6 million, and adjusted EBITDA climbed 107% to $19.9 million, driven largely by its patient affordability platform, which saw revenue soar by 167.8%. Despite challenges in the plasma segment and regulatory uncertainties, the company forecasts strong growth and improved operating margins for 2026.
DA Davidson Reiterates Buy Rating for Paysign (NASDAQ:PAYS)
DA Davidson has reiterated a "Buy" rating for Paysign (NASDAQ:PAYS) with a $9.00 price target, suggesting a 70% upside. Other analysts also show a "Moderate Buy" consensus with an average target of $9.42. Paysign recently reported mixed Q1 earnings, missing EPS estimates but exceeding revenue expectations, and institutional ownership remains significant with firms like Goldman Sachs increasing their stakes.
PaySign, Inc. (NASDAQ:PAYS) Q4 2025 Earnings Call Transcript
PaySign, Inc. (NASDAQ:PAYS) held its Q4 and full-year 2025 earnings call, reporting strong growth with full-year revenue up 40.5% to $82 million and net income increasing 98% to $7.6 million. The company's patient affordability business was a primary growth driver, with annual revenue growing 168% year-over-year, alongside continued stability in its plasma donor compensation business. PaySign provided a positive outlook for 2026, expecting revenue growth of 30% to 35% and significant margin expansion, driven by its differentiated dynamic business rules technology in the patient affordability segment and anticipated advancements in its plasma division.
Executive pay and 2026 board, auditor votes at Paysign (NASDAQ: PAYS)
Paysign (NASDAQ: PAYS) will hold its 2026 annual shareholder meeting on May 8, 2026, where shareholders will vote on the election of seven directors and the ratification of Baker Tilly US, LLP as the auditor for 2026. The company's executive compensation is heavily equity-based, with the CEO receiving $2.75 million in 2025, including significant restricted stock grants tied to performance targets. Insiders and directors collectively control approximately 21.6% of the voting power, and the board is largely independent.
Copay aid became Paysign’s growth engine, lifting pharma revenue 168%
Paysign, Inc. reported strong financial results for Q4 and full-year 2025, with total annual revenue jumping 40.5% to $82 million, largely driven by its patient affordability offerings. Pharma revenue surged by 167.8% due to increased programs and claims processing, while plasma revenue also saw a 4.0% increase. The company delivered record top- and bottom-line figures, with Adjusted EBITDA more than doubling, and provided an optimistic outlook for 2026 with projected revenue growth of 30.0% to 35.0%.
Paysign Q4 Earnings Call Highlights
Paysign (NASDAQ: PAYS) reported robust Q4 and full-year 2025 results, with revenue up 40.5% to $82.0 million and net income doubling to $7.6 million, largely driven by its rapidly expanding patient affordability platform. The company ended 2025 with $21.1 million in cash and no bank debt, providing a strong financial position for future growth. Paysign provided an optimistic 2026 outlook, projecting revenue between $106.5 million and $110.5 million, highlighting continued growth in patient affordability and a stable plasma donor compensation business.
Paysign, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results; Patient Affordability Drives 40% Revenue Growth and Significant Margin Expansion
Paysign, Inc. (NASDAQ: PAYS) announced strong financial results for the fourth quarter and full-year 2025, driven significantly by its patient affordability offerings. The company reported a 40.5% increase in total revenues to $82.0 million for the full year, with patient affordability revenue surging by 167.8%. Paysign also provided an optimistic outlook for 2026, projecting continued revenue growth and margin expansion, with anticipated net income nearly doubling.
Paysign (NASDAQ:PAYS) Given New $11.00 Price Target at Lake Street Capital
Lake Street Capital increased its price target for Paysign (NASDAQ:PAYS) from $10.00 to $11.00, maintaining a "buy" rating, indicating a potential upside of 117.35%. This news follows Paysign's strong Q4 financial results, which reported revenue of $22.76 million, exceeding estimates, and projected 30-35% revenue growth for 2026. Despite a slight EPS miss, the stock surged 34.2% to $5.06, driven by positive sentiment around its future growth targets and increased institutional investment.
DA Davidson reiterates Paysign stock Buy rating on strong Q4 growth
DA Davidson reaffirmed its Buy rating and $9.00 price target for Paysign Inc. (NASDAQ:PAYS) after the company reported strong fourth-quarter results, exceeding analyst forecasts for revenue and adjusted EBITDA. Paysign also provided optimistic 2026 guidance, projecting significant year-over-year growth in both revenue and adjusted EBITDA, further supporting DA Davidson's positive outlook. The company's recent Q4 2025 earnings also met EPS expectations and surpassed revenue forecasts, indicating robust financial health.
Paysign Projects Unprecedented Revenue Growth Amid Record 2025 Earnings
Paysign Inc.'s stock surged over 30% following a strategic partnership announcement and record-breaking 2025 earnings, with revenue up 40.5% and net income nearly doubling. The company projects continued strong growth for 2026, with an acquisition further enhancing its market position and potential to double previous year's numbers. This performance has sparked significant investor optimism and market buzz.
